Author  
Place of duty  
Title   비호지킨씨 림프종에서 CAMP - MOB 복합화학요법의 치료효과 ( Treatment of Intermediate - grade Non - Hodgkin's Lymphomas with CAMP - MOB Combination Chemotherapy )
Publicationinfo   1992 Jan; 024(01): 102-109.
Key_word   Non-Hodgkins lymphoma, CAMP-MOB combination chemotherapy
Full-Text  
Abstract   Between January 1988 to December 1988, the CAMP-MOB combination chemotherapy (cyclophosphamide 400 mg/m IV day l, adriamycin 40 mg/m IV day 1, procarbazine 100 mg/m PO day 1-10, prednisolone 40 mg/m day 1-10, methotrexate 200 mg/m IV day 8, vincristine 1.4 mg/m IV day 14, and bleomycin 15 mg/m' day l4 every 3 weeks) had been administered in 20 patients with intermediate grade non-Hodgkins lymphomas. Camplete remission rate was 80% and the median remission duration of complete responders was 20 months. The median survival of overall patients was 23 months and two year survival rate was 50%(two year disease-free survival rate: 35%). Compiete responders had a prolonged survival in comparison with partial responders or non-responders, but other factors such as the stage, B symptom, LDH level, bone marrow involvement didnt influence remission duration or overall survivaL Non-hematologic toxicity was mild and manageable but hematologic toxicity was significant, with two treatment-related deaths. Based on these findings, we concluded that CAMP-MOB combination chemotherapy could induce complete remission in high proportion of intermediate-grade non-Hodgkins lymphoma patients. However, because of short remission duration, it had no advantages over the other regimens in terms of overall and disease-free survivaL
저 자   ,서창인(Chang In Suh),김흥태(Heung Tae Kim),신동복(Dong Bok Shin),이재훈(Jae Hoon Lee),허대석(Dae Seog Heo),방영주(Yung Jue Bang),박선양(Seon Yang Park),김병국(Byoung Kook Kim),김노경(Noe Kyeong Kim)